Clinical Trials on Atrophy, Disuse in Luxembourg

Total 64 results

Boehringer Ingelheim

Approved for marketing

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

HIV Infections

Belgium, Brazil, Canada, Denmark, El Salvador, Greece, Italy, Portugal, Spain
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Pfizer
AstraZeneca

Completed

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Metastatic Breast Cancer

Korea, Republic of, United States, Canada, United Kingdom, Australia, Taiwan, Netherlands, Italy, Japan, Belgium, Ireland, Ukraine, Portugal, Germany, Romania, Russian Federation, Turkey
Stemline Therapeutics, Inc.

Active, not recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Australia, United Kingdom, Hungary, France, Portugal, Belgium, Ireland, Argentina, Austria, Canada, Denmark, Greece
Boehringer Ingelheim

Completed

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philip... and more
AstraZeneca

Completed

Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge (EPICOR)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Unstable Angina | ACS

Brazil, France, Italy, Mexico, Spain, Turkey, United Kingdom, Germany, Poland, Romania, Denmark, Finland, Norway, Argentina, Belgium, Netherlands, Greece, Luxembourg, Slovenia, Venezuela
Pfizer
International Collaborative Cancer Group

Completed

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer (IES)

Breast Neoplasms

Australia, Denmark, Netherlands, United States, Bulgaria, Hungary, Italy, Spain, Belgium, Czech Republic, Ireland, Poland, Russian Federation, Sweden, United Kingdom, Croatia, Serbia, Germany, Bosnia and Herzegovina, Norway, South... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Novartis

Approved for marketing

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Neoplasms, Breast

China, United States, Spain, United Kingdom, Austria, Belgium, Estonia, Canada, Netherlands, Singapore, Australia, Germany, Israel, Italy, Poland, Russian Federation, Sweden, Switzerland, Taiwan, Thailand, Brazil, Denmark, Ireland, Korea... and more
Novartis Pharmaceuticals

Completed

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (COMPLEEMENT-1)

Breast Cancer

United States, Belgium, Canada, Italy, Spain, United Kingdom, Austria, Czechia, Hungary, Malaysia, Saudi Arabia, Taiwan, Argentina, France, Israel, Netherlands, Russian Federation, Hong Kong, Thailand, Lebanon, Bulgaria, Denmark, Po... and more
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Canada, Taiwan, United Kingdom, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, India, Belgium, New Zealand, Austria, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more

Clinical Trials on Atrophy, Disuse in Luxembourg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations